Efficacy of KISQALI + letrozole in a first-line postmenopausal patient population.

KISQALI + letrozole is proven to deliver efficacy in the first-line setting with an AI1

KISQALI + letrozole demonstrated a statistically significant improvement in PFS vs placebo + letrozole, with a 43% reduction in risk of disease progression.1


PFS per investigator assessment1

Adapted from KISQALI Summary of Product Characteristics.1

MONALEESA-2: N=668 (no previous systemic chemotherapy for advanced disease), double-blind, placebo-controlled, 1:1 randomisation, multicentre, phase III trial in postmenopausal women with HR+/HER2− aBC. As 1L in advanced disease. No prior endocrine therapy for aBC. KISQALI 600 mg or placebo orally once daily (3 weeks on/1 week off) + AI (letrozole 2.5 mg continuous).3 The primary endpoint was locally assessed progression-free survival and the key secondary endpoint was overall survival. Other secondary endpoints included the overall response rate (complete or partial response), the clinical benefit rate (overall response plus stable disease lasting 24 weeks or more), safety, and quality-of-life assessments.3

KISQALI demonstrated tumour shrinkage as early as 8 weeks2

In MONALEESA-2, 75% of patients treated with KISQALI + letrozole saw their tumours shrink at week 8 vs 67% with placebo + letrozole.2

Change in tumour size from baseline in all patients with measurable disease at the first post-baseline evaluation (week 8)

Adapted from Janni W, et al. 2018.2


Results reported at 8 weeks were not prespecified and are observational in nature; as such, there was no prespecified statistical procedure controlling for type 1 error.

KISQALI is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.1

1L, first line; aBC, advanced breast cancer; AI, aromatase inhibitor; CI, confidence interval; HR, hazard ratio; HR+/HER2−, hormone receptor-positive/human epidermal growth factor 2-negative; mPFS, median progression-free survival; PFS, progression-free survival.

  1.  KISQALI (ribociclib). Summary of Product Characteristics.
  2. Janni W, et al. Breast Cancer Res Treat. 2018;169:469–479.
  3. Hortobagyi GN, et al. N Engl J Med. 2016;375(18):1738–1748.
Rate this content: 
No votes yet
UK I July 2021 I 126695

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]